NO147243C - Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater

Info

Publication number
NO147243C
NO147243C NO770109A NO770109A NO147243C NO 147243 C NO147243 C NO 147243C NO 770109 A NO770109 A NO 770109A NO 770109 A NO770109 A NO 770109A NO 147243 C NO147243 C NO 147243C
Authority
NO
Norway
Prior art keywords
phtaland
derivatives
preparation
therapeutic active
analogy procedure
Prior art date
Application number
NO770109A
Other languages
English (en)
Norwegian (no)
Other versions
NO770109L (no
NO147243B (no
Inventor
Klaus Peter Boegesoe
Anders Stausboell Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO147243(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of NO770109L publication Critical patent/NO770109L/no
Publication of NO147243B publication Critical patent/NO147243B/no
Publication of NO147243C publication Critical patent/NO147243C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO770109A 1976-01-14 1977-01-13 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater NO147243C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (3)

Publication Number Publication Date
NO770109L NO770109L (no) 1977-07-15
NO147243B NO147243B (no) 1982-11-22
NO147243C true NO147243C (no) 1983-03-02

Family

ID=9722860

Family Applications (2)

Application Number Title Priority Date Filing Date
NO770109A NO147243C (no) 1976-01-14 1977-01-13 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO1996001C NO1996001I1 (no) 1976-01-14 1996-01-05 Citalopram

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1996001C NO1996001I1 (no) 1976-01-14 1996-01-05 Citalopram

Country Status (19)

Country Link
US (1) US4136193A (OSRAM)
JP (1) JPS52105162A (OSRAM)
AT (1) AT359488B (OSRAM)
AU (1) AU509445B2 (OSRAM)
BE (1) BE850401A (OSRAM)
CA (1) CA1094087A (OSRAM)
CH (3) CH626886A5 (OSRAM)
DE (1) DE2657013C2 (OSRAM)
DK (1) DK143275C (OSRAM)
ES (1) ES454980A1 (OSRAM)
FI (1) FI63754C (OSRAM)
FR (1) FR2338271A1 (OSRAM)
GB (1) GB1526331A (OSRAM)
IE (1) IE44055B1 (OSRAM)
NL (2) NL192451C (OSRAM)
NO (2) NO147243C (OSRAM)
NZ (1) NZ183001A (OSRAM)
SE (1) SE429551B (OSRAM)
ZA (1) ZA7757B (OSRAM)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
CA2291067C (en) * 1997-07-08 2002-07-30 H. Lundbeck A/S Method for the preparation of citalopram
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
EP1042310B1 (en) 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
HK1042297B (zh) 1998-10-20 2004-09-10 H‧隆德贝克有限公司 製備西酞普蘭的方法
HRP20010418A2 (en) 1998-12-08 2002-06-30 Lundbeck & Co As H Benzofuran derivatives, their preparation and use
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
CZ300408B6 (cs) 1998-12-23 2009-05-13 H. Lundbeck A/S Zpusob výroby 5-kyanoftalidu
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
CZ296537B6 (cs) * 1999-04-14 2006-04-12 H. Lundbeck A/S Zpusob výroby citalopramu a meziprodukty
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
ATE277032T1 (de) 1999-10-25 2004-10-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
CH692421A5 (de) * 1999-10-25 2002-06-14 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram.
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
DE69915713T2 (de) * 1999-12-28 2005-03-03 H. Lundbeck A/S Verfahren zur herstellung von citalopram
SK11052002A3 (sk) * 1999-12-30 2003-01-09 H. Lundbeck A/S Spôsob prípravy medziproduktu pri príprave citalopramu
IL150561A0 (en) * 2000-01-14 2003-02-12 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
NL1017417C1 (nl) 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
EP1265883A1 (en) * 2000-03-13 2002-12-18 H. Lundbeck A/S Method for the preparation of citalopram
IL151566A0 (en) * 2000-03-13 2003-04-10 Lundbeck & Co As H Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
TR200400611T4 (tr) 2000-03-14 2004-04-21 H.Lundbeck A/S Sitalopramın preparasyon metodu
PL360115A1 (en) * 2000-03-16 2004-09-06 H.Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
CA2383963A1 (en) * 2000-07-06 2002-01-17 Eva Bolzonella Method for the preparation of citalopram
PL364439A1 (en) * 2000-07-21 2004-12-13 H.Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
IS6021A (is) 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
IL144817A0 (en) * 2000-08-18 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
CA2360303C (en) * 2000-12-22 2003-08-12 Marco Villa Process for the preparation of pure citalopram
AU3920201A (en) * 2000-12-28 2001-07-09 H. Lundbeck A/S Process for the preparation of pure citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
WO2002060886A1 (en) * 2001-01-30 2002-08-08 Orion Corporation, Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
WO2002066453A1 (en) * 2001-02-22 2002-08-29 Natco Pharma Limited Process for the preparation of citalopram
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
RU2003130073A (ru) * 2001-03-09 2005-04-10 Ранбакси Лабораторис Лимитед (In) Способ получения циталопрама
IL158031A0 (en) * 2001-05-01 2004-03-28 Lundbeck & Co As H The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (OSRAM) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
PL366995A1 (en) 2001-07-31 2005-02-07 H.Lundbeck A/S Crystalline composition containing escitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
IN192863B (OSRAM) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
US7148364B2 (en) * 2002-01-07 2006-12-12 Sun Pharmaceutical Industries Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB2387844B (en) * 2002-02-27 2005-05-11 Matrix Lab Ltd Separation of impurities from a crude mixture of citalopram
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
TWI332938B (en) * 2002-03-27 2010-11-11 Bando Chemical Ind Novel 1,3,5-tris(arylamino)benzenes
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
AR040970A1 (es) * 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
WO2004016602A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
ATE388947T1 (de) * 2002-12-23 2008-03-15 Lundbeck & Co As H Escitalopramhydrobromid und ein verfahren zu dessen herstellung
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
WO2004065375A1 (en) * 2003-01-17 2004-08-05 Natco Pharma Limited Processes for the preparation of escitalopram and its precursor
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
EP1486492A3 (en) * 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
ES2319539T3 (es) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
ES2240931T3 (es) * 2003-10-28 2005-10-16 Adorkem Technology Spa Procedimiento para la preparacion de citalopram.
WO2005042473A1 (en) * 2003-10-28 2005-05-12 Wockhardt Limited Improved process for the manufacture of citalopram hydrobromide
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005053796A1 (en) * 2003-12-02 2005-06-16 B & B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2005077927A1 (en) * 2004-02-16 2005-08-25 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP2141156A1 (en) * 2004-08-23 2010-01-06 Sun Pharma Global FZE Process for Preparation of Citalopram and Enantiomers
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
GT200600165A (es) * 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
EP1910346B1 (en) 2005-07-19 2019-02-27 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20090247772A1 (en) * 2005-11-14 2009-10-01 H. Lundbeck A/S Method for the Preparation of Escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080010A1 (es) * 2006-03-24 2008-03-10 Wyeth Corp Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP1988086B2 (en) 2007-04-23 2014-11-26 Synthon B.V. Process for resolving citalopram via its (S)-enriched citalopram tartrate compound.
US8288568B2 (en) * 2007-05-18 2012-10-16 Cipla Limited Process for the preparation of escitalopram
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT3093291T (pt) 2009-10-23 2019-07-25 Janssen Pharmaceutica Nv Octa-hidropirrolo[3,4-c]pirroles dissubstituídos como moduladores de recetores de orexina
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
FI3122743T3 (fi) 2014-03-28 2023-03-02 Azevan Pharmaceuticals Inc Koostumuksia ja menetelmiä hermostoa rappeuttavien sairauksien hoitamiseksi
SG11201807597UA (en) 2016-03-10 2018-10-30 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US11628160B2 (en) 2017-09-15 2023-04-18 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (OSRAM) * 1965-03-18

Also Published As

Publication number Publication date
IE44055B1 (en) 1981-07-29
JPS52105162A (en) 1977-09-03
FI770073A7 (OSRAM) 1977-07-15
US4136193A (en) 1979-01-23
CH626886A5 (OSRAM) 1981-12-15
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
DE2657013C2 (de) 1985-11-14
CH632259A5 (de) 1982-09-30
FR2338271B1 (OSRAM) 1982-11-05
CA1094087A (en) 1981-01-20
DE2657013A1 (de) 1977-07-28
ATA947276A (de) 1980-04-15
NL7700244A (nl) 1977-07-18
NL970031I2 (nl) 1997-10-01
DK143275C (da) 1982-01-18
ES454980A1 (es) 1978-04-01
AT359488B (de) 1980-11-10
DK13177A (da) 1977-07-15
ZA7757B (en) 1977-11-30
NZ183001A (en) 1978-06-02
SE7614201L (sv) 1977-07-15
FR2338271A1 (fr) 1977-08-12
NO1996001I1 (no) 1996-01-05
NO770109L (no) 1977-07-15
JPS6135986B2 (OSRAM) 1986-08-15
FI63754C (fi) 1983-08-10
SE429551B (sv) 1983-09-12
GB1526331A (en) 1978-09-27
CH632258A5 (de) 1982-09-30
AU2107377A (en) 1978-07-13
IE44055L (en) 1977-07-14
DK143275B (da) 1981-08-03
BE850401A (fr) 1977-07-14
AU509445B2 (en) 1980-05-15
FI63754B (fi) 1983-04-29
NL192451C (nl) 1997-08-04
NO147243B (no) 1982-11-22

Similar Documents

Publication Publication Date Title
NO147243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO151411C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-aryloksy-2-hydroksy-3-alkylenaminopropan-derivater
NO151321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater
NO151463C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolinderivater
NO149586C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider
NO148453C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spirohydantoinderivater
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO144848C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 4-hydroksyfenylalkanolamin-derivater
NO148777C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antrakinon-derivater
NO149065C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater
NO145842C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive indolizinderivater
NO150044C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrazol-derivater
NO149313C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO145951C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolinderivater
NO149037C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO148488C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acyl-benzimidazol-2-derivater
NO148291C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive basisk substituerte teofyllinderivater
NO148454C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidin-dionderivater
NO145163C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive antitumorglykosider
NO146710C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylpiperazinderivater
NO143903C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-fluorpyrimidin-4-on-derivater
NO152172C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater
NO152556C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antracen-biskarbonylhydrazoner
NO146600C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater
NO147273C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive cykloheksadien-derivater